Catalyst
Slingshot members are tracking this event:
Aduro Biotech (ADRO) is set to initiate CRS-207 and aPD-1 combination trial, testing pair as treatment of mesothelioma, in second half of 2017
- Source Link:
- https://seekingalpha.com/filing/3351398
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ADRO | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 28, 2017
Occurred Source:
http://investors.aduro.com/phoenix.zhtml?c=242043&p=irol-newsArticle&ID=2283753
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Crs-207, Apd-1, Mesothelioma
